Alkahest to Present Results from Phase 2a Open Label Study of AKST4290 in wet AMD at Retina World Congress

<>

SAN CARLOS, Calif., March 14, 2019 — Alkahest, Inc., a clinical stage biotechnology company focused on developing transformative therapies to treat age-related diseases, will present the results from its open label study evaluating AKST4290 for the treatment of wet age-related macular degeneration (wAMD) in treatment-naïve patients at the Retina World Congress in Fort Lauderdale, Florida on March 24, 2019 at 11:33 a.m. EST. Presentation details can be found below:

Title: Open Label Study to Evaluate the Therapeutic Effects and Safety of ASKT4290 in Patients with Newly Diagnosed Neovascular Age-Related Macular Degeneration (nAMD)
Presenter: Michael Stewart, MD
Session: First-time Presentations of Clinical Trials and Late Breakers
Date/Time: March 24, 2019, 11:33 a.m. EST
Location: Fort Lauderdale Marriott Harbor Beach Hotel

The AKST4290-201 study is a Phase 2a clinical trial designed to evaluate the therapeutic effects and safety of a six-week oral treatment regimen of AKST4290 in patients with newly diagnosed wet AMD who are naïve to any treatment. The AKST4290-202 study is a parallel Phase 2a clinical trial designed to evaluate the therapeutic effects and safety of the same treatment regimen in patients with refractory wet AMD no longer responding to anti-VEGF therapy.  Data from AKST4920-202 will be presented later in 2019. The majority of patients across both studies experienced improvement in best-corrected visual acuity (BCVA), and there were no severe or serious adverse events reported.

In December 2018, Alkahest announced positive top-line data from both Phase 2a studies of AKST4290. AKST4290 was found to be safe and well tolerated with gains in visual acuity for both treatment-naïve and treatment refractory patient groups.            

About AKST4290
AKST4290 is an orally administered CCR3 inhibitor that blocks the action of eotaxin, an immunomodulatory protein that increases as humans age and with specific age-related diseases. By targeting eotaxin and its downstream effects, AKST4290 may reduce the hallmark inflammation and neovascularization of wet AMD while also acting more broadly to reduce inflammation associated with many age-related diseases.

About Alkahest
Alkahest is a clinical stage biopharmaceutical company dedicated to treating neurodegenerative and age-related diseases with transformative therapies targeting the aging plasma proteome. The Alkahest pipeline includes multiple therapeutic candidates ranging from selected plasma fractions to protein-targeted interventions which aim to slow the detrimental biological processes of aging. Alkahest is developing novel plasma-based therapies in collaboration with Grifols, a global healthcare company and leading producer of plasma therapies. For further information see www.alkahest.com or follow us on Twitter @AlkahestInc

Contact Information 

Elizabeth Jeffords 

Chief Commercial & Strategy Officer 

Alkahest, Inc. 
ejeffords@alkahest.com 

Media Contact 

Michael Tattory 

LifeSci Public Relations 
mtattory@lifescipublicrelations.com 

SOURCE Alkahest, Inc.

Related Links

https://www.alkahest.com

WHAT TO READ NEXT...
Netcompany Group A/S – Launch of share buyback programme

Company announcement No. 9/2021                                                                                                              6 May 2021 Launch of share buyback programmeToday, Netcompany Group A/S (“Netcompany”) announces that the Board of Directors has decided

Targovax ASA: First quarter 2021 results

OSLO, Norway, May 6, 2021 /PRNewswire/ — Targovax ASA (OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard-to-treat solid tumors, today

Athenex 收購 Kuur Therapeutics,以透過現成工程的 CAR-NKT 平台擴大細胞療法的開發

革命性的領先 NKT 細胞轉化平台技術擴展了 Athenex 細胞療法的開發能力 NKT 細胞轉導使該平台用途廣泛,因其具有嵌合抗原受體 (CAR) 和 T 細胞受體 (TCR) ,分別針對血液學和實體癌症 潛在總代價為 1.85 億美元,其中包括 7,000 萬美元的預付款(主要是 Athenex 普通股)和 1.15 億美元的開發里程碑 紐約水牛城, May 06,

Initiation of new share buyback program

Based on the continued solid business performance and GN’s capital structure policy, and in accordance with the authorization granted to the Board of Directors at